Next steps include replication in independent cohorts with standardized clinical annotation, followed by orthogonal confirmation of FKBP5 and CLDN4 in tumor and NAT (e.g., qPCR and immunohistochemistry) and exploratory evaluation of potential circulating readouts, ideally in prospective perioperative studies with covariate-adjusted and subtype-aware analyses. The gene discussed is BRD2; the disease is neoplasm.